Data, Models, and Modalities: Key Themes from the Certainty 2026 Discovery UGM
A recap of the Certainty 2026 Discovery UGM in Boston, covering the top themes from…
CertaraJune 15, 2026
Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk
Certara integrates D360 with Secondary Intelligence to help drug researchers identify off-target safety risks earlier…
CertaraJune 12, 2026
Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making
Certara was reappointed to a 4 year EMA and ECDC framework contract to generate real-world…
CertaraJune 11, 2026
2026 Simcyp Workshops
Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…
CertaraJune 11, 2026
QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials
QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…
CertaraJune 11, 2026
Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations
June 30, 2026 - 12:00 PM – 2:00 PM
CertaraJune 10, 2026
Model Smarter, Not Harder: Introducing Model Designer
June 30, 2026, 10:00 – 11:00 AM ET | July 2, 2026, 10:00 – 11:00…
Danielle PillsburyJune 10, 2026
Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study
Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…
CertaraJune 9, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.
CertaraJune 9, 2026
